<DOC>
	<DOC>NCT00569114</DOC>
	<brief_summary>This is a multicenter, open-label, phase 1, dose escalation study. The purpose is to determine the highest dose of TG01 that can be safely given to patients with Non-Small Cell Lung Cancer in combination with erlotinib.</brief_summary>
	<brief_title>Phase 1 Study of TG01 and Erlotinib in Non-small Cell Lung Cancer (NCSLC) Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Inclusion Criteria (include but are not limited to): Histogically or pathologically determined relapsed/recurrent Stage IIIb (plueral effusion) or IV NSCLC. Measurable or evaluable disease as defined by RECIST Must have failed at least one prior chemotherapy regimen or have refused chemotherapy. ECOG perfromance status of 0,1, or 2. Exclusion Criteria (include but are not limited to): Radiation therapy (excluding CNS therapy) &lt; 2 weeks, chemotherapy, noncytotoxic investigational agents or high dose corticosteroids within 3 weeks of intitating therpy or patients who have not recovered from adverse effects due to agents administered more than 3 weeks earlier. Evidence of New York Heart Associatation Class III or greater cardiac disease. History of myocardial infarction, stroke, or cardiovascular intervention within the last 12 months. Patients on antiplatlet drugs or anticoagulants such as Placix and Coumadin. Systemic central nervous system metastases. The patient must be stable after radiotherapy for &gt;/= to 2 weeks and off corticosteroids for &gt;/= to 1 week. Pregnant or nursing women. Patients who are primarily refactory to erlotinib.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
</DOC>